27 Mar

Analysts Are Bullish on Axsome Therapeutics in March

WRITTEN BY Margaret Patrick

Analysts’ recommendations and target price

Wall Street analysts expect an upside potential of 88.28% for Axsome Therapeutics (AXSM) based on the company’s closing price on March 26. Analysts first revised downwards the company’s target price from $24.00 in January to $23.25 in February but then revised it upwards to $27.00 in March. The current consensus analyst recommendation for the stock is a “strong buy.”

Analysts Are Bullish on Axsome Therapeutics in March

Of the four analysts covering Axsome Therapeutics, two are recommending a “strong buy,” and two are recommending a “buy.” On March 26, Axsome Therapeutics closed at $14.34, 12.24% lower than its previous closing price, 639.18% higher than its 52-week low of $1.94 and 12.45% lower than its 52-week high of $16.38. The company’s market capitalization is $485.98 million, and thus is a small capitalization stock. Axsome Therapeutics may prove to be a riskier investment for the retail investor as compared to the broader market or large-cap stocks.

Based on its closing price on March 26, Axsome Therapeutics has reported returns of 10.73% in the last week, 55.36% in the last month, and 551.82% in the last quarter. The company has reported returns of 341.23% in the last half year, 446.29% in the last year, and 408.51% YTD.

Growth trends

In the fourth quarter, Axsome Therapeutics reported non-GAAP EPS of -$0.32, which is lower than the consensus estimate by $0.03. According to the company’s fourth-quarter earnings investor presentation, Axsome Therapeutics is currently studying four investigational therapies such as AXS-05 in treatment-resistant depression, agitation in Alzheimer’s disease, major depressive disorder, and smoking cessation indications, AXS-07 in the migraine indication, AXS-12 in the narcolepsy indication, and AXS-09 in CNS (central nervous system) disorders. The company expects to enjoy patent protection for these therapies until 2034 or 2036.

According to the company’s fourth-quarter earnings investor presentation, Axsome Therapeutics has cash worth $52.6 million on its balance sheet. The company expects to sustain its operations at least until the fourth quarter of fiscal 2021 with its own cash balance.

Latest articles

19 Jul

Afya's IPO Sees Strong Listing Gains

WRITTEN BY Mohit Oberoi, CFA

Afya (AFYA) listed on the Nasdaq Global Select Market on July 19. The company priced its IPO at $19 per share.

19 Jul

What to Watch For in Amazon's Q2 Earnings

WRITTEN BY Sanmit Amin

e-Commerce giant Amazon (AMZN) is scheduled to report its second-quarter earnings results after the closing bell on July 25.

19 Jul

Barrick Gold Reaches Deal to Buy Acacia Mining

WRITTEN BY Anuradha Garg

After a long standoff, Barrick Gold (GOLD) and Acacia Mining (ABGLF) have reached an agreement.

19 Jul

Comcast Shares Pop on Goldman's Optimism

WRITTEN BY Ruchi Gupta

Comcast (CMCSA) shares popped after Goldman Sachs issued a positive note on the company recently. Goldman upgraded its rating for Comcast to "buy" from "hold."

19 Jul

Why Analysts Are Bearish on Netflix Stock

WRITTEN BY Aditya Raghunath

Netflix stock fell over 10.0% on Thursday and is down 0.5% today as well.

On Thursday, pet retailer Chewy (CHWY) reported its first-quarter results after the market closed. The company reported its earnings for the first time.